Roundup

Five things for pharma marketers to know: Tuesday, May 24, 2022

Jack O'Brien

May 24, 2022

5:00 am

EU health agency warns Monkeypox could be endemic; FDA lifts clinical hold on Ocugen’s COVID vax trial; Moderna debuts on Fortune 500.

Five things for pharma marketers to know: Monday, May 23, 2022

Lecia Bushak

May 23, 2022

5:00 am

WHO calls emergency meeting to discuss growing Monkeypox outbreak; Telehealth abortion groups seek to bolster privacy defenses; Bayer pulls out of $670 million CAR-T partnership with Atara following patient death.

Five things for pharma marketers to know: Friday, May 20, 2022

Jack O'Brien

May 20, 2022

5:00 am

CDC advisory committee approves COVID boosters for kids between 5-11; FDA head says the baby formula should ease ‘within days’; U.S. places $119 million order for 13 million Monkeypox vaccines.

Five things for pharma marketers to know: Thursday, May 19, 2022

Lecia Bushak

May 19, 2022

5:00 am

U.S. health officials consider authorizing second booster shots for people under age 50; CDC notes concern over monkeypox outbreak in U.K.; Remix Therapeutics announces $70 million in new funding to develop RNA processing tech.

Five things for pharma marketers to know: Wednesday, May 18, 2022

Jack O'Brien

May 18, 2022

5:00 am

U.S. COVID death count tops 1 million; House Democrats introduces $28 million bill to address baby formula shortage; FDA authorizes Pfizer’s COVID booster for kids between 5 and 11.

Five things for pharma marketers to know: Tuesday, May 17, 2022

Lecia Bushak

May 17, 2022

5:00 am

Bristol Myers Squibb’s Opdivo/Yervoy combo for bladder cancer fails in Phase III study; Former FDA digital health chief joins Google; Seagan CEO resigns following domestic violence allegations.

Five things for pharma marketers to know: Monday, May 16, 2022

Jack O'Brien

May 16, 2022

5:00 am

How many lives could have been saved with COVID vaccinations?; Baby formula shortage benefits Abbott stock; Novavax eyes FDA approval for COVID vaccine in June.

Five things for pharma marketers to know: Friday, May 13, 2022

Jack O'Brien

May 13, 2022

5:00 am

NIH licenses spike protein technology to WHO; Massachusetts pays $56 million to outbreak victims at veterans’ care center; Drug overdose deaths reach a new high.

Five things for pharma marketers to know: Thursday, May 12, 2022

Jack O'Brien

May 12, 2022

5:00 am

Senate fails to codify abortion protections; Takeda posts full-year profit decline; Inovio replaces CEO.

Five things for pharma marketers to know: Wednesday, May 11, 2022

Lecia Bushak

May 11, 2022

5:30 am

Pfizer buys Biohaven; Biogen and Eisai submit Alzheimer’s drug for accelerated approval; Novavax announces first profitable quarter.

Five things for pharma marketers to know: Tuesday, May 10, 2022

Jack O'Brien

May 10, 2022

5:00 am

COVID cases likely to rise this summer; Pharmacies to pay in federal opioid trial; WHO and Gavi not buying vaccines from Aspen Pharmacare.

Five things for pharma marketers to know: Monday, May 9, 2022

Lecia Bushak

May 9, 2022

5:00 am

FDA restricts use of J&J vaccine; Companies pledge to help cover employees’ abortion costs; Telehealth startup Cerebral stops prescribing Adderall.

Five things for pharma marketers to know: Friday, May 6, 2022

Jack O'Brien

May 6, 2022

5:00 am

COVID killed 15 million worldwide; Next abortion battle to focus on pills?; NYC may reimpose mask mandates, vaccine checks.

Five things for pharma marketers to know: Thursday, May 5, 2022

Lecia Bushak

May 5, 2022

5:00 am

Demand for abortion pills to rise if Roe is overturned?; Amazon’s PillPack reaches settlement over insulin prices; CVS Health sees 11% increase in Q1 sales.

Five things for pharma marketers to know: Wednesday, May 4, 2022

Jack O'Brien

May 4, 2022

5:00 am

Health leaders warn of measles epidemic; Opioid distributors reach $518M settlement; David Sabatini withdraws from NYU job consideration.